La Presse Médicale

Sommaire

Numéro précédent

• Éditorial

  • ·Vasculitides: Roads traveled and avenue to pursue

    Page :491-492

    Loïc Guillevin

    Plan Plan

• Lectures

  • ·L1. Pathogenesis of ANCA-associated vasculitis: Observations, theories and speculations

    Page :493-498

    J. Charles Jennette, Ronald J. Falk

    Plan Plan  
  • ·L2. Neutrophil transmigration in vivo: Mechanisms, dynamics and contribution to dissemination of systemic inflammation

    Page :498-499

    Sussan Nourshargh

    Plan Plan  
  • ·L3. Are mononuclear cells predominant actors of endothelial damage in vasculitis?

    Page :499-503

    Wayel H. Abdulahad, Alexandre W.S. De Souza, Cees G.M. Kallenberg

    Plan Plan
  • ·L4. Eosinophils: How they contribute to endothelial damage and dysfunction

    Page :503-507

    Florence Roufosse

    Plan Plan
  • ·L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

    Page :507-510

    Jean-François Cordier, Vincent Cottin, Loïc Guillevin, Elisabeth Bel, Paolo Bottero, Klaus Dalhoff, Marc Humbert, Romain Lazor, Renato A. Sinico, Pasupathy Sivasothy, Michael E. Wechsler

    Plan Plan
  • ·L6. Eosinophilic granulomatosis with polyangiitis: Future therapies

    Page :510-512

    Frank Moosig

    Plan Plan
  • ·L7. Animal models of PR3-ANCA vasculitis: Approaches and controversies

    Page :512-515

    Mark A. Little

    Plan Plan
  • ·L8. Animal models of ANCA associated vasculitis: The contribution of autoantibodies and autoreactive T cells

    Page :515-517

    Peter Heeringa

    Plan Plan
  • ·L9. The role of genetic background in an animal model of ANCA-associated vasculitis

    Page :517-520

    Hong Xiao

    Plan Plan  
  • ·L10. Animal models of ANCA-associated vasculitis: Effector mechanisms and experimental therapies

    Page :520-523

    Adrian Schreiber

    Plan Plan
  • ·L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: Therapeutic options

    Page :523-527

    Patrice Cacoub, Benjamin Terrier, David Saadoun

    Plan Plan
  • ·L12. Rheumatoid arthritis vasculitis

    Page :527-530

    Xavier Puéchal

    Plan Plan
  • ·S1. Rituximab for ANCA-associated vasculitis: The experience in the United States

    Page :530-532

    Jeremy M. Clain, Ulrich Specks

    Plan Plan
  • ·S2. Rituximab for ANCA-associated vasculitis: The UK experience

    Page :532-534

    David Jayne

    Plan Plan
  • ·S3. Rituximab for ANCA-associated vasculitides: The French experience

    Page :534-536

    Pierre Charles, Loïc Guillevin

    Plan Plan
  • ·L13. Apoptosis, Apoptotic cell clearance and resolution of inflammation

    Page :536-537

    Adriano G. Rossi

    Plan Plan
  • ·L14. Immunomodulatory properties of apoptotic cells

    Page :537-543

    Sylvain Perruche, Philippe Saas

    Plan Plan  
  • ·L15. EULAR/ACR 2012 classification criteria for polymyalgia rheumatica

    Page :543-546

    Eric L. Matteson, EULAR/ACR Study Group for Development of Classification Criteria for Polymyalgia Rheumatica

    Plan Plan
  • ·L16. The specificities of pediatric vasculitis classification

    Page :546-550

    Cigdem Yildiz, Seza Ozen

    Plan Plan
  • ·L17. What can we expect from the revised Chapel Hill consensus conference nomenclature of vasculitis?

    Page :550-555

    J. Charles Jennette

    Plan Plan  
  • ·L18. Granuloma formation in granulomatosis with polyangiitis

    Page :555-558

    Konstanze Holl-Ulrich

    Plan Plan  
  • ·L19. Lymphoid neogenesis in vascular chronic inflammation

    Page :558-560

    Antonino Nicoletti, Jamila Khallou-Laschet, Kevin Guedj, Marc Clement, Anh-Thu Gaston, Marion Morvan, Charles-Antoine Dutertre, Jean-Baptiste Michel, Olivier Thaunat, Giuseppina Caligiuri

    Plan Plan
  • ·L20. Memory T-cells in vasculitis

    Page :560-563

    Peter Lamprecht

    Plan Plan
  • ·L21. Kidneys in ANCA-associated vasculitis: What to learn from biopsies?

    Page :563-565

    Chinar Rahmattulla, Annelies E. Berden, Ingeborg M. Bajema

    Plan Plan
  • ·L22. Crescent formation: Unraveling local mediators that break glomerular epithelial cell tolerance to immune injury

    Page :565-568

    Carole Hénique, Cécile Fligny, Pierre-Louis Tharaux

    Plan Plan  
  • ·L23. Renal transplantation in ANCA-associated vasculitis

    Page :568-571

    Mårten Segelmark

    Plan Plan
  • ·L24. Local treatments of subglottic and tracheal stenoses in granulomatosis with polyangiitis (Wegener’s)

    Page :571-574

    Niels Rasmussen

    Plan Plan  
  • ·L25. Medical treatment of subglottic stenosis in granulomatosis with polyangiitis (Wegener’s)

    Page :575-576

    Paul A. Monach

    Plan Plan
  • ·L26. How antigens influence the disease: An immunologist point of view

    Page :577-579

    Meghan E. Free, Dominic J. Ciavatta, Ronald J. Falk

    Plan Plan
  • ·L27. Antibodies versus phenotypes: A clinician’s view

    Page :579-582

    David Jayne

    Plan Plan
  • ·L28. Relevance of detection techniques for ANCA testing

    Page :582-584

    Csernok Elena

    Plan Plan
  • ·L29. Relevance of anti-LAMP-2 in vasculitis: Why the controversy

    Page :584-588

    Renate Kain

    Plan Plan
  • ·L30. Assessment of vasculitis extent and severity

    Page :588-589

    Nicolò Pipitone, Giulia Pazzola, Francesco Muratore, Carlo Salvarani

    Plan Plan
  • ·L31. A GWAS in ANCA-associated vasculitis: Will genetics help re-define clinical classification?

    Page :589-591

    Paul A. Lyons, Kenneth G.C. Smith

    Plan Plan
  • ·L32. ANCA vasculitis over the world. What do we learn from country differences?

    Page :591-593

    Richard A. Watts, David Gi Scott

    Plan Plan
  • ·L33. Neutrophil in immunity: A key modulator

    Page :594-595

    Marco A. Cassatella

    Plan Plan
  • ·L34. Neutrophils in ANCA-associated vasculitis: Still under investigation

    Page :595-597

    Véronique Witko-Sarsat

    Plan Plan
  • ·L35. Fc receptors and cell activation

    Page :598-599

    Renato C. Monteiro

    Plan Plan
  • ·L36. Evidence-based clinical science and art in the diagnosis of central nervous system vasculitis

    Page :600-602

    Leonard H. Calabrese

    Plan Plan
  • ·L37. Reversible cerebral vasoconstriction syndrome: Distinction from CNS vasculitis

    Page :602-604

    Anne Ducros

    Plan Plan
  • ·L38. How to treat primary vasculitis of the central nervous system

    Page :605-607

    Christian Pagnoux, Hubert de Boysson

    Plan Plan
  • ·L39. Fulminant anca vasculitis

    Page :607-609

    Alexandre Karras, Christian Jacquot, Eric Thervet

    Plan Plan
  • ·L41. Perspectives on the treatment of giant cell arteritis

    Page :609-612

    Carol A. Langford

    Plan Plan
  • ·L42. Morbidity in patients with ANCA-associated vasculitis

    Page :612-616

    Lorraine Harper

    Plan Plan
  • ·L43. Seropositive and negative ANCA-associated vasculitis, anti-MPO and PR3-vasculitis: Different outcomes?

    Page :616-619

    Julia U. Holle

    Plan Plan
  • ·L44. Management of relapses in vasculitis

    Page :619-622

    Luc Mouthon

    Plan Plan
  • ·L45. Aortitis, retroperitoneal fibrosis, and IgG4-related disease

    Page :622-625

    John H. Stone

    Plan Plan  
  • ·L46. Novel forms of clinical vasculitis: Anti-GBM vasculitis (Goodpasture’s disease)

    Page :625-628

    Stephen P. McAdoo, Charles D. Pusey

    Plan Plan
  • ·L47. Single-organ vasculitis: Conceptual and practical considerations

    Page :628-634

    Alfred Mahr, Maxime Battistella, Jean-David Bouaziz, Séverin Chaigne-Delalande

    Plan Plan  
  • ·L48. The challenges in assessing Takayasu arteritis

    Page :634-635

    Paul Bacon, Ramnath Misra

    Plan Plan
  • ·L49. Percutaneous interventions in Takayasu arteritis

    Page :635-637

    George Joseph

    Plan Plan
  • ·L50. The future of international clinical trials in vasculitis

    Page :637-641

    Peter A. Merkel

    Plan Plan
  • ·L51. From immunosuppression to selective treatments: The benefit–risk ratio

    Page :641-643

    Loïc Guillevin

    Plan Plan
  • ·L52. Vasculitis treatment: Is it time to change the standard of care for ANCA-associated vasculitis?

    Page :643-650

    Gary S. Hoffman

    Plan Plan  

• Abstracts

  • ·Calprotectin amplifies the inflammatory response

    Page :651

    R. Pepper, S. Hamour, H.H. Wang, T. Vogl, T. Cook, C. Pusey, A. Salama

    
  • ·Proteinase 3induces shape change in platelets through activation of the Rho/Rho-kinase signaling pathway

    Page :651

    X. Peng, T. Kurz, C. Brommesson, M. Grenegård, M. Segelmark

    
  • ·Identification of target antigens of anti-endothelial cell antibodies in patients with ANCA-associated systemic vasculitis: A proteomic approach

    Page :651-652

    A. Régent, H. Dib, G. Bussone, N. Tamas, C. Federici, C. Broussard, L. Guillevin, L. Mouthon

    
  • ·Proteinase 3 (PR3) is a phosphatidylserine-binding protein that can bind microparticles: Relevance in the context of granulomatosis with polyangiitis (GPA)

    Page :652

    M. Pederzoli-Ribeil, F. Angelot, A. Millet, C. Kantari, N. Reuter, L. Mouthon, P. Frachet, P. Saas, V. Witko-Sarsat

    
  • ·Orthotopic heart transplantation in eosinophilic granulomatosis with polyangiitis

    Page :652-653

    M. Groh, G. Masciocco, E. Kirchner, A. Kristen, G. Bortman, S. Varnous, M. Rosenberg, A. D’armini, C. Pellegrini, A. Brucato, G. Gregorini, M. Frigerio, J.J. Scali, L. Calabrese, L. Guillevin

    
  • ·Cluster analysis to explore subclassification of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)

    Page :653

    T. Neumann, F. Moosig, A. Vaglio, J. Zwerina, P. Bremer, A. Gioffredi, J. Grosskreutz, C. Kroegel, F. Maritati, M. Resche-Rigon, A. Mahr

    
  • ·Spleen tyrosine kinase (SYK) inhibition in experimental autoimmune glomerulonephritis (EAG)

    Page :653-654

    S.P. Mcadoo, J. Reynolds, J. Smith, G. Bhangal, E. Masuda, T.H. Cook, C.D. Pusey, F. Tam

     
  • ·Serum biomarkers signature identifies patients with overt B-cell non-Hodgkin lymphoma associated with mixed cryoglobulinemia in chronic HCV infection

    Page :654

    B. Terrier, W. Chaara, G. Geri, D. Saadoun, M. Rosenzwajg, D. Sène, A. Six, D. Klatzmann, P. Cacoub

    
  • ·Characterization of drug-induced ANCA vasculitis at Massachusetts’s general hospital (MGH): 1989–2012

    Page :654-655

    W. Pendergraft, M. Mcgrath, A. Murphy, P. Murphy, K. Laliberte, J. Niles

     
  • ·High genetic diversity in nasal Staphylococcus aureus isolates from Granulomatosis with Polyangiitis (GPA) patients

    Page :655

    M.M. Van Timmeren, C. Glasner, T. Stobernack, T.F. Omansen, E.C. Raangs, J.W. Rossen, J.P. Arends, G.A. Kampinga, W.J.B. Van Wamel, A. Rutgers, C.A. Stegeman, C.G.M. Kallenberg, P. Heeringa, J.M. Van Dijl

    
  • ·Neutrophils in ANCA vasculitis – old and apathetic

    Page :655-656

    T. Hellmark, Å. Pettersson, D. Selga, A. Bengtsson, Å. Johansson

    
  • ·Phagocytosis of apoptotic cells expressing PR3 impaired macrophage anti-inflammatory reprogramming

    Page :656

    A. Millet, J. Mocek, M. Pederzoli-Ribeil, F. Cormier, V. Baud, V. Witko-Sarsat

    
  • ·ANCA disease patients have defective Treg function exacerbated by expansion of a suppression-resistant effector population

    Page :656

    M. Free, D. Bunch, J.A. Mcgregor, C. Poulton, B. Jones, E. Berg, S. Hogan, Y. Hu, G. Preston, C. Jennette, R. Falk, M. Su

    
  • ·Unraveling the identity of FoxP3+ regulatory T cells in GPA-patients

    Page :656-657

    W.H. Abdulahad, C.A. Stegeman, M.G. Huitema, P.C. Limburg, A. Rutgers, P. Heeringa, C.G.M. Kallenberg

    
  • ·Performance of the ACR classification criteria as diagnostic criteria for granulomatosis with polyangiitis (GPA) (Wegener’s) in a respiratory referral centre

    Page :657

    F. Contreras-Rodríguez, J. Rojas-Serrano, L.F. Flores-Suárez

    
  • ·Use of the CHCC 2012 definitions in the classification of AAV using the EMA algorithm

    Page :657

    R. Abdulkader, D.G.I. Scott, J. Mooney, S.E. Lane, R.A. Watts

    
  • ·B regulatory cells are numerically but not functionally impaired in AAV

    Page :658

    S.K. Todd, R.J. Pepper, A. Tanna, C. Mauri, A.D. Salama

    
  • ·Nasal mucosa provides a niche for autoreactive plasma cells in granulomatosis with polyangiitis (Wegener’s)

    Page :658

    J. Voswinkel, C. Brieske, E. Csernok, W. Gross, K. Holl-Ulrich, A. Mueller

    
  • ·Dutch transplantation in vasculitis (DUTRAVAS)-study: Update on the outcome of renal transplantation in ANCA-associated vasculitis (AAV) patients in the Netherlands

    Page :658-659

    A. Göçeroğlu, C. Rahmattulla, A.E. Berden, M. Reinders, M.C.R.F. Van Dijk, A.A.E. De Joode, C.J. Peutz-Kootstra, M.H.L. Christiaans, I. Noorlander, R. Goldschmeding, A.D. Van Zuilen, E.J. Steenbergen, L.B. Hilbrands, L. Harper, M.A. Little, E.C. Hagen, J.A. Bruijn, I.M. Bajema

    
  • ·Complement pathways activation in pauci-immune necrotizing glomerulonephritis with ANCA

    Page :659

    M.L. Figuères, F. Fakhouri, A. Moreau, Y. Chaabouni, L.H. Noel

    
  • ·Tracheal and bronchial stenoses in granulomatosis with polyangiitis (Wegener) (GPA)

    Page :659-660

    B. Terrier, P. Cohen, X. Puéchal, L. Mouthon, L. Guillevin, For the French Vasculitis Study Group (FVSG)

    
  • ·Rituximab therapy for granulomatous poliangeitis (Wegener’s granulomatosis) with refractory granulomatous manifestations

    Page :660

    R. Solans, F. Martinez-Valle, A. Segarra, M. Ramentol, I. Agraz, J.A. Bosch

    
  • ·Upper airway gene expression profiling in granulomatosis with polyangiitis

    Page :660-661

    P. Grayson, K. Steiling, P. Monach, M. Platt, J. Xiao, X. Zhang, Y. Alekseyev, S. Moni, A. Spira, P. Merkel

    
  • ·Both histone methylation and acetylation contribute to the aberrant upregulation of proteinase 3 (PR3) and myeloperoxidase (MPO) genes in patients with ANCA disease

    Page :661

    J. Yang, C.J. Poulton, C. Henderson, J.C. Jennette, G. Preston, R. Falk, D. Ciavatta

    
  • ·Reclassifying ANCA-associated vasculitis using the EUVAS algorithm: Epidemiology and survival from the NORVASC register

    Page :661-662

    R. Abdulkader, J. Mooney, C. Sheehy, C. Mukhtyar, D.G.I. Scott, R.A. Watts

    
  • ·A myelopoiesis gene signature during remission in ANCA-associated vasculitis reflects ongoing prednisolone therapy and does not seem to predict relapses

    Page :662

    T. Kurz, M. Weiner, C. Skoglund, S. Basnet, P. Eriksson, M. Segelmark

    
  • ·ENT involvement is related to better renal function in patients with ANCA-associated vasculitis

    Page :662-663

    C. Rahmattulla, R.A.F. De Lind Van Wijngaarden, A.E. Berden, H.A. Hauer, O. Floßmann, D.R.W. Jayne, G. Gaskin, N. Rasmussen, L.H. Noël, F. Ferrario, R. Waldherr, C.D. Pusey, E.C. Hagen, J.A. Bruijn, I.M. Bajema

    
  • ·Clinical evaluation of a rapid immunofluorescence test (IIFT) for diagnosis of ANCA-associated vasculitis

    Page :663

    L. Bianchi, S. Glionna, B. Trezzi, C. Farina, R.A. Sinico

     
  • ·Prevalence of anti-neutrophil cytoplasmic antibodies in infective endocarditis: An analysis of 109 cases

    Page :663-664

    A. Mahr, F. Batteux, S. Tubiana, M. Wolff, C. Goulvestre, T. Papo, I. Klein, F. Vrtovsnik, B. Iung, X. Duval

    
  • ·Recurrent acquired ANCA-positive agranulocytosis after cocaine exposure: A chronic disease?

    Page :664

    F. Schieppati, G. Gregorini, U. Specks, S.M. Eder, A.M. Hummel, G. Rossi

    
  • ·ANCA epitope specificity determines pathogenicity, detectability and clinical predictive value

    Page :664

    A. Roth, J. Ooi, J. Hess, M. Van Timmeren, E. Berg, C. Poulton, J. Mcgregor, M. Burkart, S. Hogan, Y. Hu, W. Winnik, P. Nachman, C. Stegeman, J. Niles, P. Heeringa, M. Free, R. Kitching, S. Holdsworth, C. Jennette, G. Preston, R. Falk

    
  • ·Characteristics and outcomes of patients with ANCA-associated vasculitis in the Czech population

    Page :664-665

    Z. Hruskova, E. Jancova, V. Lanska, J. Svojanovsky, J. Klaboch, P. Nemec, K. Zamboch, M. Kodeda, V. Hanzal, P. Nemejc, V. Tesar, On Behalf Of The Czech National Clinical Registry Of Aav 1

    
  • ·Premature ovarian failure in women with ANCA-associated vasculitis

    Page :665

    J. Tuin, J.S. Sanders, A. Hoek, C.A. Stegeman

    
  • ·Infection risk in ANCA-associated vasculitis

    Page :665-666

    M. Morgan, A. Richter, J. Flint, M. Drayson, C. Yiannakis, D. Goldblatt, L. Harper

    
  • ·A risk score for predicting short-term incidence of death or relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis

    Page :666

    C. Maldini, M. Resche-Rigon, D. Jayne, K. Westman, A. Mahr

    
  • ·Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA), polyarteritis nodosa (PAN) and microscopic polyangiitis (MPA) with no initial Five-Factor Score-defined poor-prognosis factors (FFS = 0): Baseline factors associated with cytotoxic agent and immunomodulator prescription

    Page :666

    M. Samson, X. Puéchal, H. Devilliers, C. Ribi, P. Cohen, B. Bienvenu, C. Pagnoux, L. Mouthon, L. Guillevin

    
  • ·Computerized interstitial fibrosis quantification is the most powerful histological predictor of renal outcome in ANCA-associated vasculitis

    Page :667

    C. Levi, V. Meas-Yedid, C. Daniliuc, J.C. Olivo-Marin, E. Guiard, L. Mouthon, M. Roland, L. Guillevin, C. Jacquot, A. Karras, E. Thervet

    
  • ·The necessity of the addition of interstitial pathological parameters on the glomerular histological classification to predict the long-term outcome in MPO-ANCA-associated RPGN cohort in Japan

    Page :667

    E. Muso, T. Endo, M. Itabashi, Y. Iwasaki, H. Kakita, Y. Tateishi, T. Komiya, T. Ihara, W. Yumura, T. Sugiyama, K. Joh, K. Suzuki

    
  • ·Long-term outcome in patients with both ANCA and GBM positivity

    Page :667-668

    A. Tanna, S. Mcadoo, F. Tam, T. Cairns, M. Griffith, A. Salama, J. Levy, C. Pusey

     
  • ·Granulomatosis with polyangiitis (Wegener’s) is associated with HLA-DPB1*04 and EMA6A gene variants. Evidence from a genome-wide analysis

    Page :668

    G. Xie, D. Roschandel, R. Sherva, P. Monach, Y. Lu, T. Kung, K. Carrington, S. Carette, P. Dellaripa, J. Edberg, G. Hoffman, N. Khalidi, C. Langford, A. Mahr, E.W. St. Clair, P. Seo, U. Specks, R. Spiera, J. Stone, S. Ytterberg, S. Raychaudhuri, P. De Bakker, L. Farrer, C. Amos, P. Merkel, K. Siminovitch

    
  • ·ANCA-associated vasculitis in Hispanics: An unrecognized severity

    Page :668-669

    A. Sreih, R. Mandhadi, J. Block

    
  • ·Genetic regulation of CD177 – A receptor presenting anti-neutrophil cytoplasmic antigen proteinase 3

    Page :669

    C. Eulenberg, S. Bähring, F. Luft, R. Kettritz

    
  • ·ANCA disease patients with increased expression of autoantigen genes produce an alternative PR3 transcript and synthesize autoantigen proteins

    Page :669

    E. Alderman, A. Badwar, A. Muthigi, C. Allred, J. Yang, O. Lardinois, J.C. Jenette, G. Preston, R. Falk, D. Ciavatta

    
  • ·Long-term outcomes of patients with reversible cerebral vasoconstriction syndrome (RCVS)

    Page :670

    R. Hajj-Ali, S. John, L. Calabrese, M. Stillman, S. Tepper, K. Uchino

    
  • ·Recognizing childhood inflammatory brain diseases in Canada

    Page :670

    M. Twilt, S. Sheikh, T. Cellucci, G. Chedeville, A. Kirton, A. Mineyko, H. Schmelig, D. Pohl, J. Roth, D. Cabral, A. Huber, A. Rosenberg, N. Schiff, S. Benseler

    
  • ·Factors predictive of prognosis in renal AAV – A study of 104 patients in a single UK centre

    Page :670-671

    A. Tanna, G. Laura, F. Tam, T. Cairns, M. Griffith, R. Tarzi, J. Levy, A. Salama, G. Gaskin, T. Cook, C. Pusey

     
  • ·Prognosis of patients with ANCA-associated glomerulonephritis (GN) presenting with severe renal failure

    Page :671

    T. Lee, A. Gasim, J.A.G. Mcgregor, V.K. Derebail, C.J. Poulton, S. Lionaki, S.L. Hogan, J.C. Jennette, R.J. Falk, P.H. Nachman

    
  • ·Diffuse alveolar haemorrhage (DAH) in levamisole-adultered cocaine abuser resolved by rFVIIa infusion

    Page :671-672

    E. Pecci, G. Gregorini, P. Sinigaglia, G. Bozzola, G. Tassi, P. Ferremi, N. Latronico

    
  • ·ANCA-associated vasculitis (AAV) and thrombotic michroangiopathies (TMA): A retrospective histological study

    Page :672

    L. Manenti, E. Gnappi, L. Signorini, F. Pilato, A. Vaglio, C. Buzio

     
  • ·The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK

    Page :672-673

    J. Robson, A. Kiran, J. Maskell, A. Hutchings, N. Arden, B. Dasgupta, W. Hamilton, D. Culliford, A. Emin, R. Luqmani

    
  • ·Risk of cardiovascular disease early and late after a diagnosis of giant cell arteritis

    Page :673

    G. Tomasson, C. Peloquin, A. Mohammad, T. Love, Y. Zhang, H.K. Choi, P.A. Merkel

    
  • ·Large vessel vasculitis: Estimating disease activity in patients with thoracic aortic aneurysms

    Page :673

    A. Clifford, T. Clark, D. Johnston, G. Pettersson, E. Roselli, E. Soltesz, L. Svensson, G. Hoffman

    
  • ·Assessment of disease activity in large vessel vasculitis: Initial results of an international Delphi exercise

    Page :673-674

    S.Z. Aydin, H. Direskeneli, E. Matteson, P.A. Merkel

    
  • ·Outcome and prognostic factors in elderly patients with ANCA-associated vasculitis

    Page :674

    M. Weiner, S.M. Goh, A. Mohammad, Z. Hrušková, A. Tanna, A. Bruchfeld, D. Selga, Q. Ko, K. Westman, P. Eriksson, C. Pusey, V. Tesar, A. Salama, M. Segelmark

    
  • ·Factors associated with major cardiovascular events in patients with primary systemic necrotizing vasculitides: Results of a longitudinal long-term follow-up study

    Page :674-675

    B. Terrier, C. Pagnoux, G. Chironi, A. Simon, L. Mouthon, L. Guillevin

    
  • ·Outcomes in patients with granulomatosis with polyangiitis (Wegener’s) treated with short vs. long-term maintenance therapy

    Page :675

    J. Springer, B. Nutter, C. Langford, G. Hoffman, A. Villa-Forte

    
  • ·Characteristics and outcome of patients with granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis on renal replacement therapy – Data from the ERA-EDTA registry

    Page :675

    Z. Hruskova, V.S. Stel, D.R. Jayne, V. Tesar, K.J. Jager, On Behalf Of The National/Regional Renal Registry Representatives In Europe 2

    
  • ·Occupational and environmental risk factors in chronic periaortitis: A case-control study

    Page :675-676

    M.L. Urban, S. Bonini, A. Mutti, C. Buzio, A. Vaglio

    
  • ·Behçet’s disease in Budd-Chiari Syndrome

    Page :676

    A.C. Desbois, P.E. Rautou, A. Plessier, N. Belmatoug, M. Pineton De Chambrun, B. Wechsler, M. Resche-Rigon, B. Fantin, D. Valla, P. Cacoub, D. Saadoun

    
  • ·The unmet need in Behçet’s disease: Most patients are not in complete remission in the long-term follow-up

    Page :676-677

    F. Alibaz-Oner, G. Mumcu, G. Ozen, Z. Kubilay, M. Can, S. Yılmaz Oner, T. Ergun, H. Direskeneli

     
  • ·Cutaneous vasculitis: Report of 117 cases

    Page :677

    P. Fanlo, A. Villanueva, S. Clemos, C. Perez, R. Guarch, M. Montes

    
  • ·Takayasu arteritis – An outcome study in a UK cohort

    Page :677

    T. Youngstein, J. Mason

    
  • ·Biologic agents offer an effective long-term therapeutic option for refractory Takayasu arteritis

    Page :677-678

    T. Youngstein, J. Peters, J. Mason

    
  • ·Assessment of patients with Takayasu’s arteritis in a routine clinical follow-up with Indian Takayasu Clinical Activity Score (ITAS2010)

    Page :678

    F. Alibaz-Oner, H. Direskeneli

    
  • ·A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: “MYCYC”. On behalf of the European vasculitis study group

    Page :678-679

    R. Jones, L. Harper, J. Ballarin, D. Blockmans, P. Brogan, A. Bruchfeld, M. Cid, K. Dahlsveen, J. Dezoysa, P. Lanyon, C.A. Peh, V. Tesar, A. Vaglio, M. Walsh, D. Walsh, G. Walters, D. Jayne

    
  • ·Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective study in 117 patients

    Page :679

    L. Guillevin, C. Pagnoux, A. Karras, C. Khouatra, O. Aumaitre, P. Cohen, O. Decaux, H. Desmurs-Clavel, P. Gobert, T. Quemeneur, C. Blanchard-Delaunay, P. Godmer, X. Puechal, P.L. Carron, P.Y. Hatron, N. Limal, M. Hamidou, B. Bonnotte, P. Ravaud, L. Mouthon, for the FVSG

    
  • ·Treatment of systemic necrotizing vasculitides in patients ≥ 65 years old: Results of the multicenter randomized CORTAGE trial

    Page :679-680

    C. Pagnoux, T. Quéméneur, J. Ninet, E. Perrodeau, E. Diot, X. Kyndt, B. De Wazières, J.L. Reny, X. Puéchal, P.Y. Leberruyer, O. Lidove, P. Vanhille, P. Godmer, A. Albath-Sadiki, B. Bienvenu, P. Cohen, L. Mouthon, P. Ravaud, L. Guillevin, FVSG 16

    
  • ·Randomized clinical trial of extended versus standard azathioprine maintenance therapy in newly diagnosed PR3-ANCA positive vasculitis patients at high-risk for disease relapse

    Page :680

    A.A.E. De Joode, J.S. Sanders, J.W. Cohen Tervaert, C.A. Stegeman

     

• Posters

  • ·The diagnostic value of distinguishing and reporting different perinuclear ANCA (P-ANCA) immunofluorescence patterns: A prospective study

    Page :681

    S. Perel, K. Prain, R. Wilson, R. Wong, D. Gillis, P. Hogan

    
  • ·ANCA testing in routine clinical laboratory

    Page :681-682

    I. Lochman, A. Lochmanová

    
  • ·Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis relapses? Results of a longitudinal study on 126 patients

    Page :682

    L.H. Thai, P. Charles, M. Resche-Rigon, L. Guillevin

    
  • ·Results of ANCA standardisation and their diagnostic usefulness in ANCA-associated vasculitides (AASV) in a respiratory referral centre in Mexico

    Page :682-683

    F. Contreras-Rodríguez, J. Rojas-Serrano, J.E. Figueroa-Aguirre, L.F. Flores-Suárez

    
  • ·Incidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA associated vasculitis

    Page :683

    S. Holding, M. Abuzakouk

    
  • ·Multi-center evaluation of a novel chemiluminescent rapid assay for the detection of PR3-ANCA

    Page :683-684

    M. Mahler, C. Bentow, A. Vizjak, A. Radice, J. Damoiseaux, M. Miyara, G. Engstler, E. Csernok, M. Fritzler, S. Polanski, J. Wilanska, D. Blockmans, X. Bossuyt

    
  • ·Comparison of PR3-specific ANCA assays performance for diagnosis of granulomatosis with polyangiitis (GPA)

    Page :684

    A. Radice, L. Bianchi, S. Glionna, B. Trezzi, U. Maggiore, R.A. Sinico

     
  • ·PR3-ANCA: A promising biomarker for the differentiation of ulcerative colitis and Crohn’s disease

    Page :684

    M. Mahler, C. Bentow, D. Blockmans, S. Vermeire, P. Rutgeerts, X. Bossuyt

    
  • ·The association of IgM ANCA with alveolar hemorrhage revisited

    Page :685

    J. Clain, U. Specks, J. Stone

    
  • ·Computer-aided immunofluorescence microscopy (CAIFM) for ANCA diagnostics

    Page :685

    N. Hochstrate, C. Krause, K. Ens, M. Danckwardt, C. Feirer, K. Affeldt, M. Rateike, M. Morrin, D. Wuttig, J. Voigt, K. Fechner, E. Barth, T. Martinetz, W. Stöcker

    
  • ·Patients positive for both MPO-ANCA and PR3-ANCA do not present idiopathic systemic necrotizing vasculitis

    Page :685-686

    A. Chevailler, J.-F. Augusto, J.-F. Subra, D. Lakomy, N.-O. Olsson, A.-S. Denomme, X. Puechal

    
  • ·Aklides^® – a highly versatile imaging platform for detection of ANCA

    Page :686

    I. Knütter, K. Grossmann, R. Hiemann, D. Reinhold, E. Csernok, D. Roggenbuck

    
  • ·Synergistic effect of GCSF and LPS in ANCA Vasculitis

    Page :686-687

    R. Popat, S. Freeley, M. Robson

    
  • ·Pathogenic leukocytosis and their susceptibility QTLs for vasculitis and crescentic glomerulonephritis in a model of SCG/Kj mice

    Page :687

    H. Yoshitomo, Y. Wako, M. Naoki, S. Kazuo

    
  • ·Implication of vascular endothelial cell-reactive invariant NKT cells in pathogenesis of small vessel vasculitis in rats

    Page :687

    A. Ishizu, U. Tomaru, C. Iinuma, M. Waki, M. Yamaguchi, A. Kawakami, N. Sasaki, T. Yoshiki

    
  • ·Anti TNF-⍺ drug inhibits initial process of vasculitis in animal model of Kawasaki disease

    Page :687-688

    T. Oharaseki, Y. Yokouchi, H. Yamada, N. Ohno, T. Saji, K. Suzuki, S. Naoe, K. Takahashi

    
  • ·The role of quantitative trait loci (QTL) in the pathogenesis of experimental autoimmune vasculitis (EAV)

    Page :688

    J.P. Mcdaid, A. Tanna, G. Bhangal, M.A. Little, J. Behmoaras, H.T. Cook, F.W. Tam, A.D. Salama, C.D. Pusey

     
  • ·The protective role of NADPH oxidase in ANCA-induced vasculitis

    Page :688-689

    A. Schreiber, S. Krueger, C. Luft, R. Kettritz

    
  • ·Investigating Annexin-A1 in ANCA vasculitis and glomerulonephritis

    Page :689

    P. Jukes, F. D’acquisto, R. Pepper, Y. Ghani, M. Perretti, A. Salama, M. Little

     
  • ·Immunization of NOD mice with recombinant mouse proteinase 3 causes immune complex not pauci-immune crescentic glomerulonephritis

    Page :689-690

    P. Hu, H. Xiao, R. Falk, C. Jennette

    
  • ·Infliximab for Behçet disease with aortic involvement

    Page :690

    M. Okada, M. Kishimoto

    
  • ·Infliximab treatment of resistant uveitis in Behçet disease

    Page :690

    R. Becvar, A. Landova, E. Rihova

    
  • ·Behçet’s disease in children: The Great Ormond Street Hospital experience

    Page :691

    S. Nanthapisal, D. Eleftheriou, Y. Hong, N. Klein, P.A. Brogan

    
  • ·Refractory cutaneous vasculitis associated with MAGIC syndrome: Case report

    Page :691

    M. Mellado, P. Fanlo, E. Bidegain, M. Lopez De Goicoechea, M. Garcia Carasusan, J.M. Arejola

    
  • ·Behçet’s disease and pregnancy

    Page :691-692

    N. Noel, B. Wechsler, J. Nizard, N. Costedoat-Chalumeau, D. Le Thi Huong Boutin, D. Vauthier-Brouzes, M. Dommergues, P. Cacoub, D. Saadoun

    
  • ·Outcome of neuro-Behçet: Analysis of a large cohort

    Page :692

    N. Noel, B. Wechsler, D. Le Thi Huong Boutin, D. Dormont, P. Cacoub, D. Saadoun

    
  • ·Vessel wall characteristics using high-resolution magnetic resonance imaging in reversible cerebral vasoconstriction syndrome and central nervous system vasculitis

    Page :692

    R. Cerejo, T. Hammad, E. Obusez, S. John, K. Uchino, S. Jones, F. Hui, L. Calabrese, R. Hajj-Ali

    
  • ·Vessel wall characteristics using high-resolution magnetic resonance imaging in reversible cerebral vasoconstriction syndrome and central nervous system vasculitis

    Page :693

    R. Hajj-Ali, R. Cerejo, T. Hammad, E. Obusez, S. John, K. Uchino, S. Jones, F. Hui, L. Calabrese

    
  • ·Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey

    Page :693

    B. Terrier, I. Marie, D. Launay, E. Plaisier, P. Belenotti, J.-E. Kahn, P. Rullier, X. Mariette, P. Cacoub

    
  • ·Characteristics of patients with infectious cryoglobulinemia vasculitis in the absence of HCV infection: Results from the French nationwide CryoVas survey

    Page :694

    B. Terrier, I. Marie, P. Belenotti, F. Bonnet, L. Chiche, A. Hot, J.-E. Kahn, T. Quemeneur, X. Mariette, E. Plaisier, P. Cacoub

    
  • ·Ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis/Peg-IFNa/

    Page :694-695

    D. Saadoun, S. Pol, J.M. Ziza, G. Pialoux, A. Karras, O. Lambotte, P. Cacoub

    
  • ·Many faces of cutaneous vasculitis in eosinophilic granulomatosis with polyangiitis: An excellent model for histopathology of cutaneous vasculitis

    Page :695

    K.R. Chen

    
  • ·A case of relapse of Churg-Strauss syndrome (CSS) with crescentic lesions

    Page :696

    F. Yoshikazu

    
  • ·Copy number variations of FCGR3B in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

    Page :696

    F. Bonatti, A. Gioffredi, F. Maritati, F. Alberici, M.L. Urban, A. Palmisano, E. Oliva, L. Manenti, B. Tumiati, A. Pesci, P. Fraticelli, G. Guida, G. Moroni, D. Roccatello, G. Gregorini, R.A. Sinico, T.M. Neri, C. Buzio, D. Martorana, A. Vaglio

    
  • ·Methotrexate vs cyclophosphamide as maintenance therapy in severe eosinophilic granulomatosis with polyangitiis (Churg Strauss): A subanalysis of the powercime trial

    Page :696-697

    F. Maritati, M.L. Urban, E. Oliva, F. Alberici, A. Vaglio, C. Buzio

    
  • ·Clinical assessment of asthma severity partially corresponds to sputum eosinophilic airway inflammation in allergic eosinophilic granulomatosis with polyangiitis

    Page :697

    M. Latorre, C. Baldini, V. Seccia, F. Novelli, S. Bombardieri, P.L. Paggiaro

    
  • ·Clinical value of commonly measured laboratory tests in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

    Page :697-698

    P. Grayson, P. Monach, D. Cuthbertson, S. Carette, G. Hoffman, N. Khalidi, C. Koening, C. Langford, K. Mckinnon-Maksimowicz, C. Pagnoux, P. Seo, U. Specks, S. Ytterberg, P. Merkel

    
  • ·A multicenter survey of rituximab for eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

    Page :698

    A. Hot, M.J. Guerry, R. Smith, P. Sivasothy, L. Guillevin, P. Merkel, D. Jayne

    
  • ·Limited otological eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) – a new disease subset

    Page :699

    J. Der Kureghian, N. Donnelly, P. Axon, P. Jani, D. Jayne

    
  • ·The ear, nose and throat manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

    Page :699

    J. Der Kureghian, P. Jani, D. Jayne

    
  • ·ANCA-positive and ANCA-negative phenotypes of eosinophilic granulamatosis and polyangiitis (EGPA): Outcome and long-term follow-up of 46 patients from a single Polish centre

    Page :699-700

    W. Szczeklik, B. Sokolowska, P. Kuczia, J. Gasior, M. Maga, S. Bartyzel, J. Musial

     
  • ·A scoring tool for ear, nose and throat disease activity and damage in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

    Page :700

    J. Der Kureghian, P. Jani, D. Jayne

     
  • ·Serum biomarkers during relapsing disease in eosinophilic granulomatosis with polyangiitis

    Page :700-701

    C. Dejaco, P. Monach, D. Cuthbertson, S. Carette, G. Hoffman, N. Khalidi, C. Koening, C. Langford, K. Mckinnon-Maksimowicz, P. Seo, U. Specks, S. Ytterberg, P. Merkel, J. Zwerina

    
  • ·Eosinophilic granulomatosis with polyangitis (EGPA): Clinical and immunologic expression in a single center cohort

    Page :701

    C. Baldini, M. Latorre, V. Seccia, A. Della Rossa, A. Tavoni, P.L. Paggiaro, S. Sellari Franceschini, S. Bombardieri

    
  • ·Sinonasal involvement in patients with eosinophilic granulomatosis with polyangitis (EGPA, ex Churg Strauss Syndrome): A modern look to an ancient problem

    Page :701

    V. Seccia, C. Baldini, M. Latorre, S. Fortunato, L. Cristofani-Mencacci, P.L. Paggiaro, S. Sellari-Franceschini, S. Bombardieri

    
  • ·A case of eosinophilic granulomatosis with polyangiitis (EGPA) who relapsed with saddle nose

    Page :701-702

    M. Saito, Y. Komagata, T. Takahashi, A. Isomura, S. Kawashima, K. Fukuoka, M. Karube, K. Yoshihara, S. Kaname, Y. Arimura, A. Yamada

    
  • ·Referral causes and initial diagnosis of ANCA-associated vasculitides in a pulmonary tertiary centre. Retrospective study in 90 patients

    Page :702

    L.F. Flores-Suárez, M. Alba

    
  • ·ANCA in Auckland 1998–2008

    Page :702-703

    J. De Zoysa, J. Kendrick Jones, M. Lam, M. Yehia

    
  • ·Microscopic polyangiitis in the setting of usual interstitial pneumonia

    Page :703

    K. Keogh, M. Baqir, U. Specks, G. Aughenbaugh, G. Battaglia, F. Londrino, A. Tironi, S. Monti, G. Gina

    
  • ·Incidence of granulomatosis with polyangiitis (Wegener’s) among Greenlanders

    Page :703

    M. Faurschou, M. Helleberg, N. Obel, B. Baslund

    
  • ·ANCA-associated vasculitides (AAV) from the gender point of view

    Page :703-704

    A. Radice, L. Bianchi, S. Glionna, B. Trezzi, R.A. Sinico

    
  • ·Anti-neutrophil cytoplasmic antibodies associated vasculitis frequency in Dr. Manuel Quintela university hospital

    Page :704

    N. Rodriguez Sisniega, E. Araujo, C. Buzzi, N. Garcia, P. Lopez, C. Montenegro, R. Balleste, L. Borche

    
  • ·Epidemiologic study of primary systemic vasculitides in adults in Southeastern Spain (Costa del Sol Occidental region, Málaga)

    Page :705

    C. Romero-Gómez, J.A. Aguilar-García, M.D. García De Lucas, R. Cotos-Canca, J.J. García-Alegría, J. Hernández-Rodríguez

    
  • ·Pattern of renal involvement and its correlation with outcomes in patients with small and medium vessel vasculitis – experience from a tertiary care center in India

    Page :705-706

    A. Sharma, T. Mittal, M. Rathi, R. Nada, R. Rajan, R. Minz, K. Joshi, S. Singh, V. Sakhuja

    
  • ·Pandemic influenza vaccine in granulomatosis with polyangiitis: Adequate humoral response and safety in inactive patients

    Page :706

    N.E. Aikawa, A.L. Calich, S.K. Shinjo, A.C. Medeiros, M. Levy-Neto, V.S. Viana, J.C. Moraes, M.D.C. Timenetsky, E. Bonfa, R.M. Pereira

    
  • ·The association of granulomatosis with polyangiitis and IgG4-related disease: A case series

    Page :706-707

    L. Dudley, L. Brown, J. Pettus, C. Black, N. Orzechowski

    
  • ·Multiple infections in a Filipino with polyangiitis overlap syndrome (POS)

    Page :707

    G. Racaza, L. Abrahan Iv, K.A. Reyes, E. Penserga

    
  • ·Cardiovascular risk in different variants of granulomatosis with polyangiitis (Wegener’s)

    Page :707-708

    E. Kuznetsova, S. Moiseev, P. Novikov

    
  • ·Long-term follow-up of 96 GPA patients at a single centre

    Page :708

    F. Rees, M. Al-Deiri, P. Lanyon

    
  • ·Analysis of whole-blood micro-rna profiles in PR-3-ANCA positive vasculitis

    Page :708

    T. Kirsch, A. Bertram, S. Lovric, J.K. Park, J. Becker, M. Haubitz

    
  • ·Successful pregnancy in patients with granulomatosis with polyangiitis (Wegener’s) after rituximab treatment

    Page :709

    P. Novikov, E. Kuznetsova, O. Borodin, A. Meshkov, S. Moiseev

    
  • ·Distinct eicosanoid profile in exhaled breath condensates from granulomatosis with polyangiitis (Wegener’s) patients

    Page :709

    W. Szczeklik, M. Sanak, J. Sznajd, B. Jakieła, B. Sokołowska, M. Kaszuba, A. Sawina, J. Musial

     
  • ·Alveolar hemorrhage, rectus muscle hematoma, and gastrointestinal bleeding accompanied by crescentic glomerulonephritis in a patient with PR3-ANCA disease

    Page :709-710

    Y. Cao

     
  • ·Characterization of F-18 fluorodeoxyglucose PET/CT in granulomatosis with polyangiitis

    Page :710

    D. Nelson, G. Johnson, R. Cartin-Ceba, U. Specks

    
  • ·Presentation and management of granulomatosis with polyangiitis (Wegener’s) (GPA) central nervous system (CNS) involvement

    Page :710

    G. De Luna, B. Terrier, P. Charles, C. Pagnoux, X. Puechal, P. Cohen, L. Mouthon, L. Guillevin

    
  • ·Pituitary dysfunction in granulomatosis with polyangiitis

    Page :710-711

    R. Cartin-Ceba, E. Singh, T. Peikert, K. Keogh, D. Erickson, U. Specks

    
  • ·Inter-observer reproducibility of two CT scan staging systems to evaluate sinonasal involvement in granulomatosis with polyangiitis (Wegener’s)

    Page :711

    P. Díaz, G. Faba, D. Contreras, R. Zunino, C. Ortega, F. Silva

    
  • ·Pathogenesis of atherosclerosis in granulomatosis with polyangiitis

    Page :711

    R. Hajj-Ali, G. Hoffman, R. Silverstein, T. Clark, C. Langford

    
  • ·Maintenance treatment in childhood granulomatosis with polyangiitis

    Page :712

    M. Twilt, R. Schneider, D. Hebert, E. Harvey, R. Laxer, S. Dell, C. Licht, S. Benseler

    
  • ·GPA and MPA patients have different serum cytokine profiles

    Page :712

    A. Avik, Y. Sundström, L. Berg, A. Bruchfeld, V. Malmström, I. Gunnarsson

    
  • ·A case of lung biopsy-proven MPO-ANCA positive granulomatosis with polyangiitis (GPA; Wegener’s granulomatosis)

    Page :712-713

    K. Murakami, M. Saito, Y. Komagata, K. Yoshihara, S. Kaname, Y. Arimura, A. Yamada, Y. Nakamoto, M. Ishida, M. Hikgaki, H. Takizawa, R. Kawauchi, T. Goya, M. Fujiwara, T. Yazawa, H. Kamma

    
  • ·Interleukin 15, CD56+ T-cells and ANCA-associated vasculitis (AAV)

    Page :713

    B.M. Buhl, C. Stegeman, C.G.M. Kallenberg, A. Rutgers, W.H. Abdulahad

    
  • ·Resolution of proteinuria and hematuria in ANCA-associated nephritis

    Page :713

    S. Lilliebladh, A. Mohammad, K. Westman, M. Segelmark

    
  • ·Central nervous system involvement in granulomatous polyangiitis (GPA)

    Page :714

    O. Karadag, O. Helvaci, I. Dogan, U. Kalyoncu, A. Akdogan, L. Kilic, S. Kiraz

    
  • ·Clinical manifestations of granulomatosis with polyangiitis (Wegener’s granulomatosis) in the upper respiratory tracts

    Page :714

    O. Iaremenko, L. Petelytska

    
  • ·Immunopathology of active and remitting granulomatosis with poyangiitis (Wegener’s)

    Page :714-715

    L. Rani, R. Minz, A. Sharma, S. Anand, D. Gupta, N. Panda, V. Sakhuja

    
  • ·Tracheobronchial stenoses (TBS) in granulomatosis with polyangiitis (Wegener) (GPA)

    Page :715

    C. Girard, V. Cottin, J.-F. Cordier, L. Guillevin

    
  • ·Wegener or Churg Strauss

    Page :715

    S. Saliba

    
  • ·Predicting relapse in granulomatosis with polyangiitis: The role of biomarkers

    Page :716

    P. Hogan, R. O’connell, E. Browne, S. Scollard, E. Hackett, C. Feighery

    
  • ·Circulating gamma delta T cells are significantly reduced in granulomatosis with polyangiitis

    Page :716

    S. Scollard, B. Mangan, D. Doherty, N. Conlon, C. Feighery

    
  • ·Proteinase 3 reactive T cells in patients with granulomatosis with polyangiitis

    Page :716

    S. Scollard, R. Comerford, N. Conlon, C. Feighery

    
  • ·Vitamin D level is decreased in patients with Takayasu’s arteritis

    Page :716-717

    F. Alibaz-Oner, O. Asmaz Haliloglu, D. Gogas Yavuz, M. Can, H. Direskeneli

    
  • ·Presence of fibromyalgia and fatigue is not increased in patients with Takayasu’s arteritis

    Page :717

    F. Alibaz-Oner, M. Can, B. Ilhan, O. Polat, H. Direskeneli

    
  • ·Impaired endothelial function in patients with Takayasu’s arteritis

    Page :717-718

    F. Alibaz-Oner, S. Yurdakul, S. Aytekin, H. Direskeneli

    
  • ·Impairment in aortic elastic properties and mechanics of carotid artery system in patients with Takayasu’s arteritis

    Page :718

    F. Alibaz-Oner, S. Yurdakul, S. Aytekin, H. Direskeneli

    
  • ·The higher response of pandemic influenza vaccination in Takayasu’arteritis: A prospectively controlled study

    Page :718-719

    A.L. Calich, S.T. Shinjo, A.C. Ribeiro, N.E. Aikawa, M. Levy-Neto, C.G. Saad, A.R. Precioso, M.D.C. Timenetsky, E. Bonfa, R.M. Pereira

    
  • ·Takayasu’s arteritis in southern Sweden

    Page :719

    A. Mohammad, T. Mandl

    
  • ·ITAS.A suggests persistent disease activity in Takayasu aorto-arteritis after 6 months induction therapy

    Page :719

    P. Bacon

    
  • ·Outcome of vascular interventions in Takayasu arteritis

    Page :720

    M. Rajappa

    
  • ·14-3-3 in large vessel vasculitis: A novel antigen

    Page :720

    R. Chakravarti, K. Gupta, L. Svensson, E. Roselli, G. Pettersson, D. Johnston, E. Soltesz, T. Daly, D. Stuehr, G. Hoffman

    
  • ·Methotrexate plus prednisone in patients with relapsing chronic periaortitis

    Page :720-721

    F. Alberici, A. Palmisano, M.-L. Urban, F. Maritati, E. Oliva, L. Manenti, S. Ferretti, R. Cobelli, C. Buzio, A. Vaglio

     
  • ·Outcome of 1516 percutaneous interventions in 401 patients with Takayasu arteritis – a single-center experience from South India

    Page :721

    G. Joseph, D. Danda

    
  • ·Aortic dissection in giant cell arteritis: A population-based study of predictors

    Page :721-722

    T. Kermani, K. Warrington, C. Crowson, G. Hunder, S. Ytterberg, S. Gabriel, E. Matteson

    
  • ·Patients with Takayasu’s arteritis having persistent acute phase response usually have an increased major vessel uptake by 18F-FDG-PET

    Page :722

    F. Alibaz-Oner, F. Dede, T. Ones, H.T. Turoglu, H. Direskeneli

    
  • ·Can serum procalcitonin help to diagnose patients with new onset giant cell arteritis?

    Page :722

    A.P. Diamantopoulos, H. Hetland, G. Myklebust, D.M. Soldal, G. Haugeberg

    
  • ·Large vessel giant cell arteritis: Clinical, imaging characteristics and outcomes

    Page :722-723

    T. Kermani, F. Muratore, C. Crowson, A. Green, E. Matteson, K. Warrington

    
  • ·Efficacy of long-term treatment with TNF inhibitors in patients with refractory Takayasu arteritis

    Page :723

    P. Novikov, I. Smitienko, S. Moiseev

    
  • ·Serum osteopontin in giant cell arteritis: A biomarker associated with sistemic inflammatory response and relapsing course

    Page :723

    S. Prieto-González, M. Corbera-Bellalta, E. Planas-Rigol, A. García-Martínez, M.A. Alba, I. Tavera-Bahillo, G. Espígol-Frigolé, J. Hernández-Rodríguez, M.C. Cid

    
  • ·ANCA-associated systemic vasculitis is associated with impaired dilatory capacity of the conduit brachial artery – a link to increased cardiovascular risk?

    Page :723-724

    P. Clausen, W. Szpirt, B. Feldt-Rasmussen

    
  • ·Normal frequencies of circulating Th1 and Th17 cells in GCA patients

    Page :724

    K. Van Der Geest, W. Abdulahad, G. Horst, A. Rutgers, E. Brouwer, A. Boots

    
  • ·Initial presentation of giant cell arteritis with ischemic optic neuropathy without headache: Report of four cases

    Page :724

    V. Duro, C. Perez, P. Fanlo, I. Elejalde, M. Etxebarria, M. Gonzalez

    
  • ·Rapid control of disease activity by Tocilizumab in ten “difficult-to-treat” cases of Takayasu arteritis

    Page :725

    R. Goel, D. Danda, S. Kumar, G. Joseph

    
  • ·Chronic periaortitis and autoimmune thyroiditis: A novel association

    Page :725

    M.L. Urban, G. Ceresini, A. Palmisano, D. Corradi, E. Usberti, C. Buzio, A. Vaglio

    
  • ·Tocilizumab in refractory Takayasu arteritis: Case series and literature review

    Page :725-726

    N. Abisror, A. Mekinian, C. Lavigne, M.-A. Vandenehende, M. Soussan, O. Fain

     
  • ·Study of side effects of glucocorticoid treatment in 28 patients with giant cell arteritis (GCA)

    Page :726

    E. Huarte, P. Fanlo, B. Lacruz, U. Gutierrez, F. García Bragado, F. Jimenez, R. Arnáez

    
  • ·Leflunomide as a corticosteroid-sparing agent in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR): A consecutive case series

    Page :726-727

    H. Hetland, G. Myklebust, A.P. Diamantopoulos

    
  • ·Tocilizumab for the treatment of giant cell arteritis: Extended follow-up

    Page :727

    S. Unizony, B. Keroack, J.H. Stone

    
  • ·Severe relapse of Takaysu arteritis on ongoing treatment with tocilizumab

    Page :727

    R. Gunnarsson, Ø. Midtvedt, Ø. Palm, E. Merckoll, K. Johnsrud

    
  • ·Asymptomatic myocardial ischemic disease in Takayasu’s arteritis: Detection by magnetic resonance imaging

    Page :728

    C. Comarmod, P. Cluzel, N. Costedoat-Chalumeau, R. Isnard, F. Koskas, P. Cacoub, D. Saadoun

    
  • ·Systemic large vessel vasculitis pattern in chronic periaortitis: Identification of a new disease subset

    Page :728

    A. Palmisano, M.L. Urban, F. Alberici, F. Maritati, C. Salvarani, C. Buzio, A. Vaglio

    
  • ·A single centre experience of 40 children with Takayasu arteritis from India

    Page :728-729

    R. Goel, D. Danda, S. Kumar, G. Joseph

     
  • ·IgG4 in chronic periaortitis

    Page :729

    E. Oliva, F. Maritati, A. Palmisano, F. Alberici, C. Buzio, A. Vaglio

    
  • ·Takayasu arteritis (TA) and sacroiliitis. A large vessels vasculitis masquerade from anti-TNF alpha therapy

    Page :729

    P. Toniati, A. Tincani

    
  • ·ITAS.A suggests persistent disease activity in Takayasu aorto-arteritis (TA) after induction therapy

    Page :729-730

    R. Misra, D.P. Misra, D. Danda, A. Lawrence, P.A. Bacon

    
  • ·Chronic asymptomatic aortic dissection (AD) in Takayasu’s arteritis (TA); how to treat?

    Page :730

    S.T. Tosounidou, D.C. Carruthers

    
  • ·Contribution of anti-ferritin antibodies to the diagnosis of giant cell arteritis

    Page :730-731

    A. Regent, K.H. Ly, A. Blet, C. Agard, X. Puéchal, N. Tamas, C. Le-Jeunne, E. Vidal, L. Guillevin, L. Mouthon

    
  • ·Increased migration and proliferation potential characterized vascular smooth muscle cells from patients with giant cell arteritis

    Page :731

    A. Regent, K. Ly, G. Clary, C. Philippe, B. Cédric, C. Le-Jeunne, E. Vidal, A. Brezin, V. Witko-Sarsat, L. Guillevin, L. Mouthon

    
  • ·Takayasu arteritis in Tunisia: Clinical study of 34 cases

    Page :731

    I. Ben Ghorbel, N. Belfeki, S. Souissi, A. Hamzaoui, T. Ben Salem, M. Khanfir, M. Lamloum, M. Miled, H. Houman

    
  • ·Radiological features in Takayasu’ arteritis in Tunisia. About 34 cases

    Page :731-732

    N. Belfeki, I. Ben Ghorbel, S. Souissi, A. Hamzaoui, T. Ben Salem, M. Khanfir, M. Lamloum, M. Miled, H. Houman

    
  • ·Long-term outcome of 123 microscopic polyangiitis patients in a monocentric German cohort

    Page :732

    S. Schinke, E. Reinhold-Keller, M. Both, B. Nölle, M. Laudien, W. Gross, J. Holle

    
  • ·The role of MPO-positive cells and MPO deposition in glomerular capillary injury in patients with various glomerulonephritis

    Page :732-733

    S. Kawashima, Y. Arimura, Y. Komagata, S. Kaname, A. Yamada

    
  • ·Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan

    Page :733

    S. Furuta, A. Chaudhry, Y. Hamano, S. Fujimoto, H. Nagafuchi, S. Ozaki, H. Makino, S. Matsuo, T. Endo, E. Muso, C. Ito, E. Kusano, M. Yamagata, K. Ikeda, D. Kasiwakuma, I. Iwamoto, K. Westman, D. Jayne

    
  • ·Prediction of outcome of treatment by gene expression profiling of peripheral blood in patients with microscopic polyangiitis

    Page :733

    A. Ishizu, U. Tomaru, T. Murai, T. Yamamoto, T. Atsumi, T. Yoshiki, H. Makino, S. Ozaki

    
  • ·Serum C-reactive protein reflects the proportions of cellular crescent formation and glomerulosclerosis in patients with microscopic polyangiitis

    Page :734

    T. Iwakiri, Y. Matsuura, A. Yamashita, S. Uezono, S. Hisanaga, T. Tokura, K. Kitamura, Y. Asada, S. Fujimoto

    
  • ·Unilateral vocal cord paralysis as initial manifestation of severe microscopic polyangiitis (MPA)

    Page :734

    L.F. Flores-Suárez, G. Tona

    
  • ·Rapidly progressive glomerulonephritis is not the sole presentation of renal involvement in ANCA associated vasculitis

    Page :734-735

    C. Levi, E. Thervet, E. Guiard, L. Mouthon, C. Daniliuc, M. Roland, L. Guillevin, D. Nochy, C. Jacquot, A. Karras

    
  • ·Abnormal glycosylation of serum IgG from patients with ANCA-associated systemic vasculitis: Relation to disease activity

    Page :735

    O. Lardinois, J. Hess, L. Deterding, L. Aybar, S. Hogan, J. Mcgregor, C. Poulton, Y. Hu, C. Henderson, D. Bunch, R. Falk

    
  • ·Renal histopathological classification of ANCA associated glomerulonephritis: A validation study of 92 patients

    Page :735-736

    E. De Sousa Amorim, A. Ros Abando, A. Casian, D. Jayne

     
  • ·Aortitis evidenced by PET-CT 18FDG in the setting of ANCA-associated vasculitis: About four cases

    Page :736

    T. Nguyen, E. Cogan, D. Blocklet, F. Vandergheynst

     
  • ·The informational needs of patients with ANCA-vasculitis – a multinational study

    Page :736-737

    J. Mooney, P.A. Merkel, F. Poland, N. Spalding, D. Sheriff, P. Grayson, R. Richesson, R. Le Duc, D.G.I. Scott, R.A. Watts

    
  • ·Proposal of an algorithm for the diagnosis and aetiologic identification of diffuse alveolar haemorrhage (DAH)

    Page :737

    C. Ramírez-Assad, F. Contreras-Rodríguez, J. Cedillo, E. Bautista, L.F. Flores-Suárez

     
  • ·Validation of the Birmingham Vasculitis activity score (BVAS) and the Vasculitis Damage Index (VDI) in a population of patients with ANCA-associated vasculitis (AASV) in Mexico

    Page :737

    C. Ramírez-Assad, M.H. Cardiel, L.F. Flores-Suárez

    
  • ·Illness perceptions and fatigue in systemic vasculitis

    Page :737-738

    P. Grayson, N. Amudala, C. Mcalear, R. Leduc, D. Shereff, R. Richesson, L. Fraenkel, P. Merkel

    
  • ·Successful treatment with rituximab in patients with Schnitzler syndrome

    Page :738

    P. Novikov, E. Kuznetsova, V. Pulina, A. Meshkov, N. Nikiforova

    
  • ·Rituximab and vascular function in granulomatosis with polyangiitis (GPA)

    Page :738-739

    A. Casian, K. Maki-Petaja, J. Cheriyan, A. Hubsch, I. Wilkinson, D. Jayne

     
  • ·Serial chest high-resolution CT (HRCT) scans in patients with ANCA-associated vasculitis

    Page :739

    P. Konopasek, D. Altmanova, Z. Hruskova, E. Jancova, B. Svobodova, V. Tesar

    
  • ·Association between thyroid disease and ANCA associated vasculitis

    Page :739-740

    M. Prendecki, A. Tanna, E. Clutterbuck, C. Pusey

    
  • ·Single-organ gallbladder vasculitis: Characterization and distinction from systemic vasculitis involving the gallbladder. An analysis of 57 patients

    Page :740

    J. Hernández-Rodríguez, C.D. Tan, E.R. Rodríguez, G.S. Hoffman

    
  • ·Weight loss – a common presentation in a rare disease. IgG4 related disease (IgG4 RD) is an emerging diagnosis not to miss

    Page :740-741

    S.T. Tosounidou, D.C. Carruthers

    
  • ·Silica binds to LL-37 and CpG DNA complexes

    Page :741

    P.R. Hurtado, J. Nitschke, E. Hurtado-Perez, C.A. Peh

    
  • ·Aneurysms in the view of rheumatology perspective

    Page :741

    O. Karadag, U. Kalyoncu, L. Kilic, E. Er, A.G. Er, I. Dogan, A. Akdogan, I. Ertenli

    
  • ·IgA associated vasculitis (IgAV) – a 5-year retrospective study

    Page :741-742

    C. Gota, S. Billings, C. Langford

    
  • ·Macrophage activation syndrome in vasculitis: An underrecognised complication?

    Page :742

    L. Damian, C. Cismaru, L. Ghib, M. Muresan, B. Stancu, M. Sfichi, I. Felea, I. Filipescu, S. Rednic, A. Bojan

    
  • ·Retroperitoneal fibrosis at the onset of ANCA associated vasculitis: The risk of a delay in the diagnosis of vasculitis

    Page :742

    S. Possenti, F. Londrino, G. Jeannin, C. Salviani, G. Cancarini, G.A. Gregorini

    
  • ·Positron emission tomography scanning in ANCA associated vasculitis

    Page :742

    M. Kemna, S. Vöö, P. Van Paassen, S. Timmermans, M. Van Kroonenburgh, J.W. Cohen Tervaert

    
  • ·Circulating microRNAs in ANCA vasculitis correlate to renal function, hemoglobin and risk of relapse

    Page :743

    C. Skoglund, A.L. Carlsen, M. Weiner, T. Kurz, T. Hellmark, P. Eriksson, N. Heegaard, M. Segelmark

    
  • ·Hemorrhagic emergency due to intrahepatic aneurism rupture in a patient with Polyateritis Nodosa after long time of episodic fever: A case report

    Page :743-744

    F. Silva, M. Cisternas, G. Maguida, M.I. Ruiz, P. Diaz, S. Gonzalez, J. Martinez, L. Meneses, L. Massardo

    
  • ·Clinical characteristics of ANCA associated vasculitis in hispanic patients: Single centre experience in Chile

    Page :744

    M. Cisternas, M.J. Lira, F. Silva

    
  • ·Long-term outcomes of patients with Reversible Cerebral Vasoconstriction Syndrome (RCVS)

    Page :744

    S. John, L. Calabrese, K. Uchino, S. Tepper, M. Stillman, R. Hajj-Ali

    
  • ·Treatment related damage in the ANCA-associated vasculitides: An analysis of cohorts from the European Vasculitis Study Group (EUVAS) therapeutic trials

    Page :744-745

    J. Robson, H. Doll, O. Flossmann, S. Ravi, H. Lorraine, H. Peter, J. David, M. Chetan, W. Kerstin, L. Raashid

     
  • ·Factors associated with long-term damage in the ANCA-associated vasculitides: An analysis of cohorts from the European vasculitis study group (EUVAS) therapeutic trials

    Page :745

    J. Robson, H. Doll, F. Oliver, S. Ravi, H. Lorraine, H. Peter, J. David, M. Chetan, W. Kerstin, L. Raashid

    
  • ·Markers for work disability in ANCA-associated vasculitis

    Page :745-746

    N. Basu, A. Mcclean, L. Harper, M. Little, R. Luqmani, O. Flossmann, D. Jayne, N. Dhaun, V. Kumar, J. Mclaren, E. Amft, L. Erwig, G. Macfarlane, D. Reid, G. Jones

    
  • ·Long-term outcome of GPA and MPA in a population based cohort

    Page :746

    R.A. Watts, J. Mooney, C. Mukhtyar, C. Sheehy, D.G.I. Scott

    
  • ·ADAPTIV: A Delphi study to assess morbidity prevention and treatment in vasculitis

    Page :746-747

    N. Brown, D. Tooth, A. Summers, M. Venning

    
  • ·Estimating renal survival using the ANCA-associated glomerulonephritis classification: A validation study

    Page :747-748

    B. Wilde, P. Van Paassen, P. Van Breda Vriesman, J.W. Cohen Tervaert, M. Hilhorst

     
  • ·Towards an international standardized ENT disease activity score in GPA

    Page :748

    M. Martinez Del Pero, M. Laudien, N. Rasmussen

    
  • ·Cardiovascular outcomes and prognostic predictors in ANCA-associated vasculitis

    Page :748-749

    C. Yuste, A. Casian, C. Jironda, D. Jayne

    
  • ·The value of a patient global assessment for disease activity in granulomatosis with polyangiitis

    Page :749

    G. Tomasson, J.C. Davis, G.S. Hoffman, W.J. Mccune, U. Specks, R. Spiera, E.W. St. Clair, J.H. Stone, P.A. Merkel

    
  • ·Patient reported outcomes in ANCA-associated vasculitis. A prospective comparison between BVAS and RAPID3 on an MDHAQ

    Page :749

    O. Elsallabi, J. Block

    
  • ·Severe fatigue and psychological morbidity in ANCA-associated vasculitis

    Page :749-750

    A. Mcclean, N. Basu, D. Jones, M. Morgan, J. Bosch, L. Harper

    
  • ·Severe fatigue in ANCA-associated vasculitis is associated with altered perception and reduced cardiovascular fitness

    Page :750

    A. Mcclean, N. Basu, D. Jones, M. Morgan, J. Bosch, L. Harper

    
  • ·Predicting renal relapse with the histopathologic classification of ANCA-associated glomerulonephritis

    Page :750-751

    A. Göçeroğlu, R.A.F. De Lind Van Wijngaarden, A.E. Berden, K. Westman, O. Flossmann, M. Walsh, M. Fiocco, R. Wolterbeek, H.A. Hauer, D. Jayne, G. Gaskin, N. Rasmussen, L.H. Noël, F. Ferrario, R. Waldherr, C. Pusey, E.C. Hagen, J.A. Bruijn, I.M. Bajema

    
  • ·Antineuthropil cytoplasmic autoantibody-associated vasculitis (AAV) in older patients (REVAS Study)

    Page :751

    R. Solans, L. Caminal, G. Fraile, L. Saez, J.J. Rios, M. Monica, X. Xavier, M. Monica, C.M. Jesus

    
  • ·ANCA vasculitis and atypical hemolytic uremic syndrome: An association with poor outcome

    Page :752

    E. Gnappi, L. Signorini, A. Vaglio, F. Pilato, L. Manenti

     
  • ·Long-term outcome of severe alveolar hemorrhage in ANCA-associated vasculitis: A retrospective cohort study

    Page :752

    Z. Hruskova, A. Casian, P. Konopasek, B. Svobodova, D. Frausova, V. Lanska, V. Tesar, D. Jayne

    
  • ·Acute respiratory distress syndrome (ARDS) as primary manifestation in ANCA-associated vasculitis

    Page :752-753

    M. Dolch, M. Irlbeck, M. Wessely, S. Rau, L. Frey, U. Schönermarck

    
  • ·Focal necrotizing and crescentic glomerulonephritis in patients with normal serum creatinine

    Page :753

    S.P. Mcadoo, A. Tanna, O. Randone, M. Griffith, J. Levy, T. Cook, T. Cairns, C. Pusey

    
  • ·Clinical and pathological study on 34 patients with primary ANCA-associated systemic vasculitis with renal immune complex deposition

    Page :753

    X. Li, W. Zhang, X. Pan, N. Chen

    
  • ·Long-term outcome of low dose cyclophosphamide (CYC) and plasma exchange (PLEX) induction in ANCA-associated vasculitis (AAV)

    Page :754

    W. Szpirt, E. Krarup, M. Egfjord

    
  • ·Longitudinal ANCA measurements for predicting a relapse are useful in patients with severe disease but not in patients with limited disease

    Page :754

    M. Kemna, J. Damoiseaux, J. Austen, B. Winkens, J. Peters, P. Van Paassen, J.W. Cohen Tervaert

    
  • ·Low %CD5+ B cells in patients with ANCA vasculitis portends a shorter time to relapse after rituximab

    Page :754-755

    D. Bunch, J. Mcgregor, L. Aybar, E. Studstill, Y. Hu, S. Hogan, K. Colby, C. Poulton, C. Mendoza, J. Schmitz, R. Falk, P. Nachman

    
  • ·Monocyte chemoattractant protein-1 (MCP-1) in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis: Biomarker potential and association with polymorphisms in the MCP-1 and the CC chemokine receptor-2 (CCR2) gene

    Page :755

    N. Jönsson, L. Gunnarsson, A. Pettersson, S. Ohlsson

    
  • ·Abundant neutrophil extracellular traps in thrombus of patient with microscopic polyangiitis

    Page :755

    D. Nakazawa, U. Tomaru, S. Jodo, S. Nishio, T. Atsumi, A. Ishizu

    
  • ·Characterization of regulatory B cells in ANCA-associated vasculitis (AAV)

    Page :755-756

    N. Lepse, W.H. Abdulahad, A. Rutgers, C.A. Stegeman, C.G. Kallenberg, P. Heeringa

    
  • ·Epitope analysis of anti-myeloperoxidase antibodies in patients with ANCA-associated vasculitis

    Page :756

    S.J. Gou, P.C. Xu, M. Chen, M.H. Zhao

    
  • ·Investigating the microRNA signature of ANCA associated vasculitis

    Page :756-757

    N. Brown, S. Harris, M. Venning, P. Brenchley

    
  • ·The interaction between C5a and sphingosine-1-phosphate in neutrophils for ANCA-mediated activation

    Page :757

    J. Hao, C. Wang, M. Chen, M.H. Zhao

    
  • ·Circulating level of high mobility group box-1 is associated with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis

    Page :757-758

    C. Wang, M. Chen

    
  • ·Pentraxin-3 and soluble tumor necrosis factor-like weak inducer of apoptosis (s-Tweak) in anti-neutrophil antibody associated vasculitis (AAV)

    Page :758

    M. Wendt, O. Borjesson, A. Avik, J. Bratt, A.R. Qureshi, I. Gunnarsson, A. Bruchfeld

    
  • ·Epitope analysis of anti-myeloperoxidase antibodies in propylthiouracil-induced ANCA-associated vasculitis

    Page :758

    C. Wang, M. Chen

    
  • ·IL-10 producing regulatory B-cells are diminished in ANCA-associated vasculitis

    Page :758-759

    B. Wilde, M. Thewissen, P. Van Paassen, M. Hilhorst, J. Damoiseaux, O. Witzke, J.W. Cohen Tervaert

    
  • ·Interleukin-21, B cell activating factor and unmethylated CpG oligodeoxynucleotides synergize in promoting anti-Proteinase 3 autoantibody production in vitro

    Page :759

    N. Lepse, J. Land, A. Rutgers, C.G. Kallenberg, C.A. Stegeman, W.H. Abdulahad, P. Heeringa

    
  • ·DNA from neutrophil extracellular traps is hypomethylated

    Page :759

    E. Hurtado, J. Nitschke, P. Hurtado, C.A. Peh

    
  • ·ANCA reactive B cells and neutrophils cross-talk in the pathogenesis of AAV: A model proposal

    Page :760

    P.R. Hurtado, J. Nitschke, E. Hurtado-Perez, C.A. Peh

    
  • ·Tissue destruction in granulomatosis with polyangiitis: Common histological pattern in mice and men

    Page :760

    N. Kesel, U. Schumacher, M. Laudien, K. Holl-Ulrich, W. Gross, A. Müller, S. Ullrich

    
  • ·Coagulation activity in renal ANCA-positive vasculitis

    Page :760-761

    A.E. Ekstrand, R.L. Lassila, L.J.K. Joutsi-Korhonen, A.S. Salmela

    
  • ·Galactosylation and sialylation of anti-proteinase 3 antibodies in granulomatosis with polyangiitis is associated with increased inflammatory cytokines

    Page :761

    M. Morgan, K. Stavenhagen, C. Koeleman, A. Hipgrave-Ederveen, L. Harper, B. Jacobs, C. Savage, R. Jefferis, A. Deelder, M. Wuhrer

    
  • ·LAMP-2, a potential novel receptor on human monocytes derived dendritic cells (MDDC)

    Page :761-762

    D.L. Leone

    
  • ·Autoantibodies for several antigens in neutrophil cytoplasm other than PR3 and MPO also promote release of NETs from neutrophils

    Page :762

    Y. Komagata, S. Amonpatumrat, K. Sano, S. Kawashima, S. Kaname, Y. Arimura, A. Yamada

    
  • ·Antibodies to LAMP-2 alter lysosome function and attenuate chaperone-mediated autophagy in human macrophages

    Page :762

    K. Sintiprungrat, V. Thongboonkerd, P. Andrea, R. Kain, A.J. Rees

    
  • ·Urinary HMGB1 levels are associated with CD4+ T-cells in urine in patients with ANCA-associated vasculitis and active nephritis

    Page :762-763

    A.W. Silva De Souza, W.H. Abdulahad, J. Westra, P. Sosicka, P.C. Limburg, M. Bijl, C.A. Stegeman, C.G.M. Kallenberg

    
  • ·HMGB1 in ANCA-associated vasculitis: A longitudinal study

    Page :763

    A.W. Silva De Souza, J. Westra, J. Bijzet, P.C. Limburg, M. Bijl, C.A. Stegeman, C.G.M. Kallenberg

    
  • ·Functionally effect regulatory B cells in patients with active ANCA vasculitis

    Page :763

    L. Aybar, S. Hogan, J. Mcgregor, J. Vick, C. Poulton, Y. Hu, C. Henderson, R. Falk, D. Bunch

    
  • ·In vitro neutrophil activation by ANCA from patients with ANCA associated vasculitis; degranulation and oxidative burst

    Page :764

    S. Ohlsson, S. Ohlsson, L. Holm, L. Gunnarsson, T. Hellmark

    
  • ·Potential defect in annexin-A1-dependent anti-inflammatory mechanisms in GPA: Its cleavage by PR3 and its inhibition by autoantibodies

    Page :764

    M. Pederzoli-Ribeil, A. Regent, A. Millet, F. D’acquisto, L. Guillevin, M. Perretti, L. Mouthon, V. Witko-Sarsat

    
  • ·Thrombotic vasculopathy with neovascularisation associated with probably levamisole-contaminated cocaine: Report of 2 cases

    Page :764-765

    L.F. Flores-Suárez, M.A. Martínez-Velasco, S. Toussaint-Caire, A. Rodríguez-Carreón, M. Díaz-Lozano, K. Sánchez-Armendáriz

     
  • ·Cutaneous hypersensitivity vasculitis associated with visceral Mycobacterium tuberculosis infection: A report of three cases

    Page :765

    M. Areses, C. Perez, J. Ibañez, M. Fanlo, M. Abinzano, M. Cia

    
  • ·Severe diffuse alveolar haemorrhage after TAVI with CoreValve in patient with AAV and Horton disease in remission. An immuno-allergic reaction?

    Page :765-766

    G.A. Gregorini, C. Fiorina, M.F. Bonetti

    
  • ·Microscopic vasculitis associated to Sjögren’s syndrome. About 4 cases

    Page :766

    I. Ben Ghorbel, N. Belfeki, T. Ben Salem, A. Hamzaoui, M. Khanfir, M. Lamloum, M. Miled, H. houman

    
  • ·Quantifying the effect of rituximab on changes in serum immunoglobulin G

    Page :766-767

    D. Roberts, R. Smith, R. Jones, F. Alberici, H. Marco, D. Jayne

    
  • ·Risk of malignancy with long-term immunosuppression in ANCA-associated vasculitis

    Page :767

    C. Rahmattulla, A. Göçeroğlu, M.E.J. Reinders, E.C. Hagen, J.A. Bruijn, I.M. Bajema

    
  • ·Infectious complications related to treatment in an inception cohort of antineutrophil cytoplasmic antibody associated vasculitis

    Page :767

    J. Mcgregor, R. Negrete-Lopez, C. Poulton, J. Kidd, S. Weaver, L. Goetz, Y. Hu, P. Nachman, R. Falk, S. Hogan

    
  • ·Cyclophosphamide effect on immunoglobulins levels in AAV patients treated with long-term pre-emptive rituximab maintenance

    Page :767-768

    E. Besada, W. Koldingsnes, J. Nossent

    
  • ·An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis (RITAZAREM)

    Page :768

    D. Jayne, R. Smith, P. Merkel

     
  • ·C5aR inhibitor on leukocytes exploratory ANCA associated renal vasculitis (CLEAR) clinical trial with orally administered CCX168

    Page :768-769

    A. Bruchfeld, M. Schaier, M. Jadoul, D. Selga, I. Szombati, M. Venning, P. Hamilton, K. Ciechanowski, C. Hugo, M. Segelmark, O. Viklicky, J. Jaen, T. Schall, P. Bekker

    
  • ·Lack of efficacy of tocilizumab in mucocutaneous Behçet’s syndrome: Report of two cases

    Page :769

    A.P. Diamantopoulos, G. Hatemi

    
  • ·Improving the quality and safety of intravenous cyclophosphamide (IV CYC): A regional audit of a best-practice protocol

    Page :769

    F. Rees, S. Varughese, M. Regan, K. Lim, C. Symonds, P. Lanyon

    
  • ·An open-label trial of abatacept in mild relapsing granulomatosis with polyangiitis (Wegener’s) (GPA)

    Page :770

    C. Langford, D. Cuthbertson, G. Hoffman, J. Krischer, C. Mc Alear, P. Monach, P. Seo, U. Specks, S. Ytterberg, P. Merkel

    
  • ·Lactoferrin inhibits formation of neutrophil extracellular traps in inflammation

    Page :770

    K. Okubo, M. Kamiya, Y. Urano, M. Nangaku, T. Fujita, J. Hirahashi

    
  • ·Incidence of coronary aneurysms in children with Kawasaki disease after early treatment with IVIG and aspirin: Report of 55 cases

    Page :771

    C. Romero, C. Perez, P. Martinez, R. Urabayen, P. Fanlo, T. Carrasquer

    
  • ·Co-trimoxazole monotherapy as induction therapy for localized granulomatosis with polyangiitis

    Page :771

    J. Tuin, J.S. Sanders, C.A. Stegeman

     
  • ·Successful treatment of refractory cutaneous ulcer associated with polyarteritis nodosa with bosentan

    Page :771-772

    P. Fanlo, L. Loidi, S. Clemos, A. Villanueva, E. Huarte, M. Mellado, T. Elias, C. Perez

    
  • ·Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: A randomized controlled trial. PEXIVAS

    Page :772

    B. Brezina, D. Jayne

    
  • ·Fixed-interval repeat dose rituximab improves abnormalities in the periperhal B cell compartment and reduces relapse rates in ANCA associated vasculitis

    Page :772

    E. Wallin, R. Smith, R. Jones, D. Jayne, K. Smith

    
  • ·Predictors of treatment resistance and relapse in Chinese patients with antineutrophil cytoplasmic antibody-associated disease

    Page :772-773

    Y. Cao

    
  • ·Induction treatment of ANCA associated vasculitis with a single dose of rituximab

    Page :773

    M. Little, T. Turner-Stokes, E. Sandhu, N. Stolagiewicz, C. Ashley, A. Salama, A. Burns, A. Howie, D. Dinneen

     
  • ·Therapeutic drug monitoring detects high interpatient variability in response to mycophenolic acid treatment in patients with ANCA-associated vasculitis

    Page :773-774

    M. Schaier, S. Bönisch-Schmidt, V. Schwenger, M. Zeier, C. Sommerer

    
  • ·Time to remission and relapse following rituximab in an inception cohort of antineutrophil cytoplasmic antibody associated vasculitis

    Page :774

    M.E. Studstill, J. Mcgregor, C. Poulton, Y. Hu, P. Nachman, R. Falk, S. Hogan

    
  • ·Rituximab use in patients with ANCA-associated vasculitis: Clinical efficacy and impact on immunological parameters

    Page :774

    Z. Chocova, Z. Hruskova, H. Mareckova, B. Svobodova, V. Bednarova, E. Jancova, R. Rysava, V. Tesar

    
  • ·Maintenance therapy using rituximab-induced continuous B cell depletion for ANCA vasculitis

    Page :774-775

    W. Pendergraft, F. Cortazar, J. Wenger, A. Murphy, K. Laliberte, J. Niles

     
  • ·What everybody is doing but no one is talking about: Complementary and alternative medicine (CAM) prevalence in the ANCA SVV population

    Page :775

    E. Berg, J. Mcgregor, M. Burkart, C. Poulton, S. Hogan

    
  • ·Long term follow up of patients who received repeat dose rituximab as maintenance therapy for ANCA associated vasculitis (AAV)

    Page :775-776

    R. Smith, F. Alberici, R. Jones, D. Jayne

    
  • ·Re-treatment with rituximab in ANCA-associated vasculitis only in the presence of clinical relapse: A single centre experience

    Page :776

    G. Jeannin, C. Salviani, S. Possenti, A. Regazzoli, F. Allegri, G. Cancarini, G.A. Gregorini

    
  • ·Gestational rituximab exposure in women with vasculitis

    Page :776-777

    W. Pendergraft, M. Mcgrath, A. Murphy, P. Murphy, K. Laliberte, J. Niles

    
  • ·Use of rituximab in Hispanic patients with severe ANCA associated vasculitis: A 6 years experience in a tertiary centre in Chile

    Page :777

    F. Silva, L. Massardo, M. Mimica, P. Pastenes, M. Cisternas, F. Radrigan, M. Gutierrez

    
  • ·Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in Granulomatosis with Polyangiitis: Results from a single centre

    Page :777

    E. Besada, W. Koldingsnes, J. Nossent

    
  • ·Use of an empirically derived cyclophosphamide dosing nomogram for treatment of vasculitis

    Page :777-778

    A. Salama, M.D. Gabrel, A. Koteci, L. Harper, D. Jayne, D. Nitsch, R. Daniel, E. Naylor, M. Little

    
  • ·Retreatment with Rituximab in the RAVE Trial

    Page :778

    E. Miloslavsky, U. Specks, P. Merkel, P. Seo, R. Spiera, C. Langford, G. Hoffman, C. Kallenberg, W. St. Clair, N. Tchao, L. Ding, D. Ikle, B. Jepson, P. Brunetta, J. Stone

    
  • ·Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (MAINRITSAN): Follow-up at 34 months

    Page :778-779

    B. Terrier, C. Pagnoux, A. Karras, C. Khouatra, O. Aumaitre, P. Cohen, F. Maurier, O. Decaux, H. Desmurs-Clavel, P. Gobert, T. Quemeneur, C. Blanchard-Delaunay, P. Godmer, X. Puechal, L. Mouthon, L. Guillevin

     
  • ·Safety of remission induction with rituximab versus cyclophosphamide in patients 65 and older with severe ANCA-associated vasculitis

    Page :779-780

    E. Miloslavsky, U. Specks, P. Merkel, P. Seo, R. Spiera, C. Langford, G. Hoffman, C. Kallenberg, W. St. Clair, N. Tchao, L. Ding, D. Ikle, B. Jepson, P. Brunetta, J. Stone

    

• Index des auteurs

  • ·Index auteurs

    Page :782-790